A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

Inclusion Criteria:

• Must be medically stable at the time of vaccination such that, according to thejudgment of the investigator, hospitalization within the study period is notanticipated and the participant appears likely to be able to remain on study throughthe end of protocol specified follow-up. A stable medical condition is defined asdisease not requiring significant change in therapy during the 6 weeks beforeenrollment and when hospitalization for worsening of the disease is not anticipated.Participants will be included on the basis of physical examination, medical history,and vital signs performed between informed consent form (ICF) signature andvaccination

• Participant must be: a) postmenopausal (postmenopausal state is defined as no mensesfor 12 months without an alternative medical cause); and b) not intending toconceive by any methods

• Must sign an ICF indicating that the participant understands the purpose, proceduresand potential risks and benefits of the study, and is willing to participate in thestudy

• Willing and able to adhere to the lifestyle restrictions specified in this protocol

• Agrees to not donate blood from the time of vaccination until 3 months afterreceiving the last dose of study vaccine

Exclusion Criteria:

• History of an underlying clinically significant acute or uncontrolled chronicmedical condition or significant cognitive impairment or physical examinationfindings for which, in the opinion of the investigator, participation would not bein the best interest of the participant (for example, compromise the well-being) orthat could prevent, limit, or confound the protocol-specified assessments

• Known or suspected allergy or history of severe allergic reaction, anaphylaxis, orother serious adverse reactions to vaccines or vaccine excipients

• History of severe allergic reactions (for example anaphylaxis) to any component ofthe high-dose (HD) quadrivalent seasonal influenza vaccine, including egg protein,or following a previous dose of any influenza vaccine

• Has had major surgery (per the investigator's judgment) within 4 weeks beforeadministration of the first study vaccine or will not have recovered from surgeryper the investigator's judgment at time of vaccination

• History of acute polyneuropathy (for example, Guillain-Barré syndrome) or chronicinflammatory demyelinating polyneuropathy